ApprovedFDA approval

Lytenava (bevacizumab-vikg)

Outlook Therapeutics (OTLK)

Marketer take

An approved ophthalmic bevacizumab for wet AMD, entering a market where retina specialists already use off-label compounded bevacizumab, so the pitch centers on an FDA-approved, eye-specific formulation and price.

Sponsor company
Outlook Therapeutics (OTLK)
Indication
To treat patients with neovascular (wet) age-related macular degeneration
Therapeutic area
Ophthalmology
Event
FDA approval
Date
Jul 24, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move